Mirati Therapeutics Stock Price. Everything You Need To Know About The Mirati Therapeutics Stock!
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm’s product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Mirati Therapeutics Stock Price. Everything You Need To Know About The Mirati Therapeutics Stock! performance
- Employees 587
- Company HQ San Diego
- Website https://www.mirati.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Mirati Therapeutics is a biotechnology company based in the United States that focuses on developing precision medicines for the treatment of cancer. Their innovative approach involves targeting specific genetic mutations and pathways that drive the growth of cancer cells. As an investor from Malaysia, Thailand, Indonesia, or Vietnam, you can take advantage of the investment opportunities offered by Mirati Therapeutics. By investing in this stock, you have the potential to support groundbreaking advancements in cancer treatment and potentially earn attractive returns on your investment. To get started, you can access Zorion’s easy-to-use investment platform and gain valuable insights and recommendations to make informed investment decisions. Additionally, you can avail of educational resources and materials to further enhance your knowledge about investing in Mirati Therapeutics. Start your investment journey today and be a part of the future of cancer treatment.
